Kanishk Kumar: Thalassemia Pipeline 2025 Addressing Hemoglobin Deficiencies in Inherited Blood Disorders
Kanishk Kumar, Digital Marketing Executive at DelveInsight Business Research LLP, shared a post on LinkedIn:
”Thalassemia Pipeline 2025: Addressing Hemoglobin Deficiencies in Inherited Blood Disorders
Thalassemia, a group of inherited blood disorders causing reduced hemoglobin synthesis and chronic anemia, is advancing with innovative therapies in 2025. The Thalassemia Pipeline features 25+ pharmaceutical firms developing 28+ investigational medications, from gene editing to small molecules, aimed at increasing hemoglobin levels, reducing transfusion dependency, and improving quality of life for patients with varying severity.
Key Developments in Thalassemia Treatment:
Etavopivat by Novo Nordisk, a PKR activator in Phase III, aims to improve red blood cell health and reduce anemia in thalassemia by enhancing oxygen affinity and decreasing hemolysis.
CS-101 by Correct Sequence Therapeutics, a gene editing therapy in Phase I, reactivates fetal hemoglobin production for a potential lifetime cure using the patient’s own stem cells.
Leading Thalassemia Companies include Novo Nordisk , Kind Pharmaceuticals LLC, Correct Sequence Therapeutics , Editas Medicine, San Rocco Therapeutics, Lantu Biopharma, Regeneron , Kanglin Biotec, Shanghai BDgene Co., Ltd., BioRay Pharmaceutical , Celgene, Mabwell , among others.
Promising therapies include Etavopivat, AND017, CS101, among others.
DelveInsight’s comprehensive report on the Thalassemia Pipeline Analysis 2025․՛՛

Stay updated with Hemostasis Today.
-
Nov 8, 2026, 12:22Marc Carrier: Advancing Catheter-Related Thrombosis Prevention Through Factor XI Inhibition
-
Nov 8, 2026, 11:56Why Genetic Predisposition Does Not Always Lead to Thrombosis – Stork Genetics
-
Nov 8, 2026, 11:45Sher-Lu Pai: Investigating Intracardiac Thrombosis and Its Management in Liver Transplantation
-
Nov 8, 2026, 11:25Mehmet Cilingiroglu: Navigating Anticoagulation Choices in Acute Coronary Syndrome PCI
-
Nov 8, 2026, 07:16Gilberto de lima Lopes Junior: The Cardiovascular Consequences of Cancer in Younger Patients
-
Nov 8, 2026, 06:51Haney Mallemat: Key Principles and Pitfalls of LVAD Emergencies
-
Nov 8, 2026, 06:31Maria Omer: Clinical Recognition and Management of Cavernous Sinus Thrombosis
-
Nov 8, 2026, 06:16Natasha Jolakoski: University of New Mexico Hospital Promotes PGY-2 Thrombosis and Hemostasis Management Pharmacy Residency
-
Nov 8, 2026, 05:47Safaa Hilal: POCUS in the Evaluation of Perioperative Troponin Elevation